Cargando…

Involvement of insulin resistance in D-galactose-induced age-related dementia in rats: Protective role of metformin and saxagliptin

Age-related dementia is one of the most devastating disorders affecting the elderly. Recently, emerging data suggest that impaired insulin signaling is the major contributor in the development of Alzheimer’s dementia (AD), which is the most common type of senile dementia. In the present study, we in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kenawy, Sara, Hegazy, Rehab, Hassan, Azza, El-Shenawy, Siham, Gomaa, Nawal, Zaki, Hala, Attia, Amina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568415/ https://www.ncbi.nlm.nih.gov/pubmed/28832656 http://dx.doi.org/10.1371/journal.pone.0183565

Ejemplares similares

Lactoferrin Enhanced Apoptosis and Protected Against Thioacetamide-Induced Liver Fibrosis in Rats
por: Hessin, Alyaa, et al.
Publicado: (2015)

Saxagliptin and Metformin in Fixed Combination for the Treatment of Type 2 Diabetes in Adults
por: Minze, Molly G., et al.
Publicado: (2013)

Resveratrol prevents liver fibrosis via two possible pathways: Modulation of alpha fetoprotein transcriptional levels and normalization of protein kinase C responses
por: Hessin, Alyaa Farouk, et al.
Publicado: (2017)

Adding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures
por: Neutel, Joel M., et al.
Publicado: (2013)

Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
por: Panagoulias, George S, et al.
Publicado: (2014)

Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
por: Doggrell, Sheila A
Publicado: (2014)

Renoprotective Effect of Lactoferrin against Chromium-Induced Acute Kidney Injury in Rats: Involvement of IL-18 and IGF-1 Inhibition
por: Hegazy, Rehab, et al.
Publicado: (2016)

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Kombiglyze (metformin and saxagliptin)‐induced hepatotoxicity in a patient with non‐alcoholic fatty liver disease
por: Thalha, Abdul Malik, et al.
Publicado: (2018)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Could Metformin Manage Gestational Diabetes Mellitus instead of Insulin?
por: Saleh, Hend S., et al.
Publicado: (2016)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Saxagliptin for type 2 diabetes
por: Chacra, Antonio R
Publicado: (2010)

Intranasal Chromium Induces Acute Brain and Lung Injuries in Rats: Assessment of Different Potential Hazardous Effects of Environmental and Occupational Exposure to Chromium and Introduction of a Novel Pharmacological and Toxicological Animal Model
por: Salama, Abeer, et al.
Publicado: (2016)

Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Derosa, Giuseppe, et al.
Publicado: (2011)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Dapagliflozin plus saxagliptin add‐on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes
por: Johansson, Lars, et al.
Publicado: (2020)

Anti-inflammatory effects of saxagliptin and vildagliptin against doxorubicin-induced nephrotoxicity in rats: attenuation of NLRP3 inflammasome up-regulation and tubulo-interstitial injury
por: Mostafa, Rasha Ezzat, et al.
Publicado: (2021)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Protective effect of metformin on D-galactose-induced aging model in mice
por: Fatemi, Iman, et al.
Publicado: (2018)

Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis
por: Zhuang, Yan, et al.
Publicado: (2020)

Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia
por: Bekele, Mengistu, et al.
Publicado: (2021)

Protective Effects of Vasodilatory Βeta-Blockers Carvedilol and Nebivolol against Glycerol Model of Rhabdomyolysis-Induced Acute Renal Failure in Rats
por: Atwa, Ahmed, et al.
Publicado: (2016)

Protective Effects of the Third Generation Vasodilatory Βeta - Blocker Nebivolol against D-Galactosamine - Induced Hepatorenal Syndrome in Rats
por: Atwa, Ahmed, et al.
Publicado: (2017)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Liu, Hao, et al.
Publicado: (2016)

Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment
por: Tao, Tao, et al.
Publicado: (2018)

Comparison of charges and resource use associated with saxagliptin and sitagliptin
por: Vaidya, Varun, et al.
Publicado: (2016)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

Evaluation of drug interactions of saxagliptin with sildenafil in healthy volunteers
por: Mansour, Rania Y., et al.
Publicado: (2022)

Effect of a topical copper indomethacin gel on inflammatory parameters in a rat model of osteoarthritis
por: Yassin, Nemat Z, et al.
Publicado: (2015)

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes
por: Mathieu, Chantal, et al.
Publicado: (2018)

The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial
por: Dore, Fiona J., et al.
Publicado: (2018)

Combined Intranasal Insulin/Saxagliptin/Metformin Therapies Ameliorate the Effect of Combined Oral Contraceptive- (COC-) Induced Metabolic Syndrome (MetS) with a Major Target on Glucose Metabolism in Adult Female Wistar Rats
por: Afolabi, Saheed Olanrewaju, et al.
Publicado: (2021)

Efficacy and Safety of Saxagliptin as Add-On Therapy in Type 2 Diabetes
por: Neumiller, Joshua J.
Publicado: (2014)

Triple therapy with low‐dose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes
por: Rosenstock, Julio, et al.
Publicado: (2019)

Omega-3 fatty acids ameliorate doxorubicin-induced cardiorenal toxicity: In-vivo regulation of oxidative stress, apoptosis and renal Nox4, and in-vitro preservation of the cytotoxic efficacy
por: Saleh, Dalia, et al.
Publicado: (2020)

Formulation, Optimization, In Vitro and In Vivo Evaluation of Saxagliptin-Loaded Lipospheres for an Improved Pharmacokinetic Behavior
por: Rasul, Akhtar, et al.
Publicado: (2021)

Therapeutic Experience of Saxagliptin as First Add-on after Metformin in Indian Type 2 Diabetes Patients: A Non-interventional, Prospective, Observational Study (ONTARGET-INDIA)
por: Kalra, Sanjay, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e6dm1hr9cmv5rukf7avspfk5t7